Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology... Show more
A.I.dvisor indicates that over the last year, TYRA has been loosely correlated with CGEM. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if TYRA jumps, then CGEM could also see price increases.
| Ticker / NAME | Correlation To TYRA | 1D Price Change % | ||
|---|---|---|---|---|
| TYRA | 100% | +0.64% | ||
| CGEM - TYRA | 38% Loosely correlated | +0.40% | ||
| RAPP - TYRA | 37% Loosely correlated | -14.67% | ||
| NRIX - TYRA | 35% Loosely correlated | -0.31% | ||
| RCUS - TYRA | 35% Loosely correlated | -19.58% | ||
| GOSS - TYRA | 35% Loosely correlated | +2.19% | ||
More | ||||
Industry Biotechnology
The RSI Indicator for TYRA moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 23 similar instances when the indicator left oversold territory. In 22 of the 23 cases the stock moved higher. This puts the odds of a move higher at 90%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on TYRA as a result. In 79 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for TYRA just turned positive on October 20, 2026. Looking at past instances where TYRA's MACD turned positive, the stock continued to rise in 51 of 56 cases over the following month. The odds of a continued upward trend are 90%.
Following a +6.51% 3-day Advance, the price is estimated to grow further. Considering data from situations where TYRA advanced for three days, in 248 of 293 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
TYRA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TYRA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for TYRA entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 21 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.057) is normal, around the industry mean (2.988). P/E Ratio (-8.732) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. TYRA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 92 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TYRA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.